炭疽杆菌保护性抗原在大肠杆菌中的表达及其纯化

利用基因重组技术获取炭疽杆菌保护性抗原(PA)。将炭疽杆菌保护性抗原编码基因pag与pET载体连接构建重组质粒,转化大肠杆菌DE3株,诱导表达炭疽杆菌保护性抗原,并经亲和层析及凝胶过滤纯化此抗原。实验成功构建了表达炭疽杆菌保护性抗原的重组菌株,纯化后PA纯度达90%,且经检测纯化产物具有天然PA的生物学活性。同时表明从大肠杆菌中纯化PA较以往从炭疽杆菌中获取PA简便易行。     

炭疽杆菌荚膜研究进展

本文对炭疽杆菌荚膜的本质、在感染中的作用、合成与基因调控以及免疫原性进行了回顾。炭疽杆菌荚膜的研究进展使得对炭疽感染的机制,炭疽杆菌逃避宿主免疫系统的机制,机体对炭疽的免疫应答及其作用有了深入的了解。     

炭疽杆菌致病性研究进展

炭疽杆菌是人类历史上第一个被发现的病原菌。炭疽杆菌的研究在近几年取得了较大进展 ,特别是本年度其基因组序列测定已完成并向全世界公布 ,进一步深化了对炭疽杆菌的研究。炭疽杆菌致病性的研究一直是炭疽杆菌研究的重点 ,近年来此方面的研究取得了很多新进展 ,从基因组、致病物质及致病机制 3个方面对此作一个简单的介绍。     

炭疽芽胞杆菌及炭疽疾病概述

美国炭疽恐怖事件引起了全球的广泛关注,曾经被忽略的炭疽再度成为人们关注的焦点并加剧_了人们对它的恐惧感,为认识这种细菌的毒力和致病机制,本文就炭疽芽胞杆菌的流行病学、微生物学、发病机制、临床表现及其治疗预防并结合其作为生物武器的特点等问题予以综述。     

炭疽芽胞杆菌基因芯片探针文库的构建

为制备炭疽芽胞杆菌的基因芯片探针文库,以炭疽芽胞杆菌毒素质粒pX01和荚膜质粒pX02为原材料,用Sau3A I酶切pX01和pX02质粒DNA,Taq DNA聚合酶72℃补平加A,经AT克隆,PCR初步鉴定筛选出炭疽质粒片段的阳性克隆．DNA自动分析仪对克隆片段进行序列测定;用生物信息学方法对其片段进行同源性分析;并将克隆的探针打印于玻片上,制备成炭疽芽胞杆茵基因芯片,与炭疽杆茵质粒DNA样品进行初步芯片杂交的实验,杂交实验的阳性率达到了90％以上,证明大部分克隆探针属于炭疽芽胞杆菌．炭疽芽胞杆菌基因芯片探针文库的构建为基因芯片探针的制备摸索出一条简便、高效、可行的方法．     

炭疽杆菌的致病因子与炭疽的防治

炭疽为一种人、兽共患急性传染病,部分国家将炭疽杆菌作为生物威胁因子进行研究和生产。该菌毒性与质粒PXOl、PXO2有关,PXOl产物包括水肿因子、保护性抗原和致死因子。PXO2是另一编码致病因子,产物荚膜抑制细胞的吞噬,有助病菌繁殖、扩散和建立感染。抗生素与抗炭疽血清联合应用,突变保护性抗原、水肿因子、致死因子联合注射,Al(OH)3佐剂PA疫苗,减毒口服菌苗,PA基因重组活菌苗均可抵抗炭疽杆菌致死性攻击。     

炭疽杆菌的特性和主要毒力因子

炭疽是由炭疽杆菌芽胞引起的疾病,炭疽杆菌的主要毒力因子在毒力质粒上编码pXO1和pXO2,pXO1184.5kbp大小,编码分泌外毒素的基因,此二个外毒素为二亚单位毒素,二个A蛋白,致死因子（LF,83kD)和水肿因子（EF,89kD);一个B蛋白,保护因子（PA,85kD);分别由pXO1上的独立基因,Lef,Cya和Pag编码;pXO2为95.3kbp大小的小质粒,携带三个基因,CapB,CapC和CapA,与聚-γ-D谷氨酸构成的荚膜合成有关。     

国内外炭疽研究的新进展

<正> 1966年10～11月在美国马里兰州召开的炭疽杆菌专题会议上,Nungester,W J(1967)提出了炭疽今后研究的15个问题,题目的范围很广,包括人和动物的炭疽流行病学。水土等外环境污染的消除。高原( 6000呎以上, 2000米以上)很少发病的原因( Manuel,1967),病原学包括炭疽杆菌的生活史,芽胞侵入机体的方式,芽胞发芽及感染机制,可溶性抗原的生物学和理化特性,炭疽病理生理学,类毒素和活菌苗的免疫应答,中和毒素的治疗作用等等。     

炭疽芽胞杆菌疫苗研究进展

炭疽芽胞杆菌引起的炭疽病死亡率非常高 ,当前的疫苗具有效力不稳定、对吸入性炭疽的保护率低、免疫程序繁琐、存在副作用等缺点。近年来人们在改造传统疫苗的同时又有一些新的发现 ,如保护性抗原 (PA)的抗体在体内可杀死芽胞 ;通过粘膜免疫能够诱导机体分泌IgA抗体 ;抗多聚谷氨酸 (γ D PGA)抗体可以同炭疽杆菌的繁殖体作用 ,从而杀死繁殖体 ;寻找到新的免疫原。DNA疫苗、活载体疫苗的出现为新一代安全、免疫程序简单、具更高保护率的疫苗奠定了基础     

炭疽杆菌检测方法的研究现状与展望

炭疽是严重威胁人类健康的烈性传染病,其病原体为炭疽芽孢杆菌。炭疽芽孢杆菌在我国公布的《人间传染的病原微生物名录》中被列为第二类病原微生物(高致病性病原微生物),其芽孢可作为生物战剂和生物恐怖的原材料,因此,发展灵敏、高效的炭疽杆菌检测方法十分重要和紧迫。按检测的靶标分类,针对炭疽杆菌的检测方法主要有四大类:针对炭疽杆菌芽孢的检测方法,针对细菌繁殖体的检测方法,针对炭疽杆菌基因的检测方法和针对炭疽毒素蛋白的检测方法。其中,针对炭疽杆菌芽孢和细菌繁殖体的检测已经有比较成熟的方法,但其在特异性以及临床的实用性方面难以令人满意;针对炭疽杆菌基因的检测技术在特异性和灵敏度上有较大的提高,但在临床诊断等方面还有欠缺;而针对炭疽毒素蛋白的检测技术的发展,使得直接对炭疽杆菌的主要致病因子的检测成为可能,这对于临床诊断以及流行病学研究具有重要意义。本文对当前炭疽杆菌检测方法的最新进展做了简要的归纳,关注了不同检测方法的适用范围和检测能力,并展望了相关领域的发展趋势,希望能为从事炭疽杆菌检测方法研究的同行提供参考和帮助。     

Anthrax toxins

Bacillus anthracis, the etiological agent of anthrax, secretes three polypeptides that assemble into toxic complexes on the cell surfaces of the host it infects. One of these polypeptides, protective antigen (PA), binds to the integrin-like domains of ubiquitously expressed membrane proteins of mammalian cells. PA is then cleaved by membrane endoproteases of the furin family. Cleaved PA molecules assemble into heptamers, which can then associate with the two other secreted polypeptides: edema factor (EF) and/or lethal factor (LF). The heptamers of PA are relocalized to lipid rafts where they are quickly endocytosed and routed to an acidic compartment. The low pH triggers a conformational change in the heptamers, resulting in the formation of cation-specific channels and the translocation of EF/LF. EF is a calcium- and calmodulin-dependent adenylate cyclase that dramatically raises the intracellular concentration of cyclic adenosine monophosphate (cAMP). LF is a zinc-dependent endoprotease that cleaves the amino terminus of mitogen-activated protein kinase kinases (Meks). Cleaved Meks cannot bind to their substrates and have reduced kinase activity, resulting in alterations of the signaling pathways they govern. The structures of PA, PA heptamer, EF, and LF have been solved and much is now known about the molecular details of the intoxication mechanism. The in vivo action of the toxins, on the other hand, is still poorly understood and hotly debated. A better understanding of the toxins will help in the design of much-needed anti-toxin drugs and the development of new toxin-based medical applications.Abbreviations CMG2 Capillary morphogenesis protein 2 - DTA Diphtheria toxin A chain - EF Edema factor - EFn N-terminal fragment of EF - ETx Edema toxin - GR Glucocorticoid receptors - GSK3 Glycogen synthase kinase 3 - I domain Integrin-like domain - iNOS Inducible nitric oxide synthase - LF Lethal factor - LFn N-terminal fragment of LF - LTx Lethal toxin - MAPK Mitogen-activated protein kinase - Mek MAPK kinases - PA Protective antigen - PA₂₀ 20-kDa N-terminal fragment of PA - PA₆₃ 63-kDa C-terminal fragment of PA - TEM8 Tumor endothelial marker 8     

Targeted Silencing of Anthrax Toxin Receptors Protects against Anthrax Toxins

Anthrax spores can be aerosolized and dispersed as a bioweapon. Current postexposure treatments are inadequate at later stages of infection, when high levels of anthrax toxins are present. Anthrax toxins enter cells via two identified anthrax toxin receptors: tumor endothelial marker 8 (TEM8) and capillary morphogenesis protein 2 (CMG2). We hypothesized that host cells would be protected from anthrax toxins if anthrax toxin receptor expression was effectively silenced using RNA interference (RNAi) technology. Thus, anthrax toxin receptors in mouse and human macrophages were silenced using targeted siRNAs or blocked with specific antibody prior to challenge with anthrax lethal toxin. Viability assays were used to assess protection in macrophages treated with specific siRNA or antibody as compared with untreated cells. Silencing CMG2 using targeted siRNAs provided almost complete protection against anthrax lethal toxin-induced cytotoxicity and death in murine and human macrophages. The same results were obtained by prebinding cells with specific antibody prior to treatment with anthrax lethal toxin. In addition, TEM8-targeted siRNAs also offered significant protection against lethal toxin in human macrophage-like cells. Furthermore, silencing CMG2, TEM8, or both receptors in combination was also protective against MEK2 cleavage by lethal toxin or adenylyl cyclase activity by edema toxin in human kidney cells. Thus, anthrax toxin receptor-targeted RNAi has the potential to be developed as a life-saving, postexposure therapy against anthrax.     

Anthrax vaccination strategies

The biological attack conducted through the US postal system in 2001 broadened the threat posed by anthrax from one pertinent mainly to soldiers on the battlefield to one understood to exist throughout our society. The expansion of the threatened population placed greater emphasis on the reexamination of how we vaccinate against Bacillus anthracis. The currently-licensed Anthrax Vaccine, Adsorbed (AVA) and Anthrax Vaccine, Precipitated (AVP) are capable of generating a protective immune response but are hampered by shortcomings that make their widespread use undesirable or infeasible. Efforts to gain US Food and Drug Administration (FDA) approval for licensure of a second generation recombinant protective antigen (rPA)-based anthrax vaccine are ongoing. However, this vaccine’s reliance on the generation of a humoral immune response against a single virulence factor has led a number of scientists to conclude that the vaccine is likely not the final solution to optimal anthrax vaccine design. Other vaccine approaches, which seek a more comprehensive immune response targeted at multiple components of the B. anthracis organism, are under active investigation. This review seeks to summarize work that has been done to build on the current PA-based vaccine methodology and to evaluate the search for future anthrax prophylaxis strategies.